Savara Inc. recently announced the grant of inducement awards to eight new employees who joined the organization. This move follows standard practices for attracting talent within the biopharmaceutical sector, specifically for companies focused on rare respiratory diseases.
The compensation package includes options to purchase 74,500 shares of the company’s common stock alongside 64,500 restricted stock units. These awards were finalized by the Board of Directors Compensation Committee on August 17, 2026, and align with NASDAQ Listing Rule 5635(c)(4) requirements.
The stock options carry an exercise price of $5.37 per share, which matches the closing price on the grant date. These options operate on a 10-year term and follow a quarterly vesting schedule based on the individual start dates of the new hires. In contrast, the restricted stock units vest in full upon the two-year anniversary of the respective employment start dates.
Savara continues its work in clinical-stage biopharmaceuticals with a primary focus on autoimmune pulmonary alveolar proteinosis. Their lead program, MOLBREEVI, remains in Phase 3 development. By providing these equity incentives, the company signals its intent to secure the specialized human capital necessary to advance its research and development pipeline.